Mannose binding lectin (MBL) has been proposed as an efficient therapeutic target to alleviate RRV-induced arthritis but to date only pentosan sulfate, initially approved for the treatment of cystitis in U.S., is available [19, 20]. The gene discussed is MBL2; the disease is arthritic joint disease.